Health and Healthcare Systems

This breakthrough could help 20 million people every year

Nine-year-old Tumelo shows off antiretroviral (ARV) pills before taking his medication at Nkosi's Haven, south of Johannesburg November 28, 2014.

Finding one drug that could treat all three could be a major move in treating a global issue. Image: REUTERS/Siphiwe Sibeko

Lydia Ramsey
Editorial Intern, Business Insider Science
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Health and Healthcare Systems?
The Big Picture
Explore and monitor how Health and Healthcare is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Future of Global Health and Healthcare

Diseases you've never heard of affect millions of people around the world.

These so-called neglected tropical diseases are mostly parasitic infections that have very few treatments and affect some of the hardest-hit communities.

But, there might be a glimmer of hope. Researchers at the Genomics Institute of the Novartis Research Foundation said in a letter published Monday in Nature that they have identified a new drug that could treat three of these debilitating diseases.

For now, the treatment has only been tested in mice, but ideally it could make a dent in the combined 20 million people affected by the diseases every year.

 Status of endemicity of cutaneous leishmaniasis, worldwide 2012
Image: WHO

Chagas disease, leishmaniasis, and sleeping sickness lead to 500,000 deaths a year. They're all fairly similar diseases: Chagas disease is a parasitic infection that comes from the kissing bug that got its name for biting people on the face; leishmaniasis is a parasitic infection spread by sand flies that leads to skin sores; sleeping sickness (or trypanosomiasis) is a parasitic infection that's spread by the tsetse fly, which at first can lead to headaches, fever, joint pain, and itchiness, but later can lead to some serious neurological problems.

So, the scientists figured out a compound, which they dubbed GNF6702, that might be able to treat all three.

  • For sleeping sickness, the new drug did a better job of clearing out the parasite in mice than the existing treatment. Starting out with leishmaniasis, they found that the drug worked better in mice than miltefosine, the treatment that's currently used to treat leishmaniasis. They made it work in mice, which is a good first step. After that, they pitted it against the main drug for Chagas disease, benznidazole, which is being developed by KaloBios after then-CEO Martin Shkreli acquired the rights to the drug. They found that the new compound did just as well as benznidazole at making the mice parasite-free.

Finding one drug that could treat all three could be a major move in getting the treatment advanced into later trials that could one day change the way we treat these neglected diseases. The researchers noted, "There are only scarce resources for drug development in these diseases, and identification of a common target and chemical scaffold with potential across multiple indications provides new hope for improved treatment options for some of the world’s poorest people."

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Antimicrobial resistance is a leading cause of global deaths. Now is the time to act

Dame Sally Davies, Hemant Ahlawat and Shyam Bishen

May 16, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum